A Phase 3 interventional study of Fluticasone Furoate/GW642444 and Fluticasone furoate in Asthma, sponsored by GlaxoSmithKline. Completed at 183 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one has the largest enrollment, is one of 7 that started in 2010, is one of 14 in phase 3, and was the 11th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,020 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 6th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 88th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fluticasone Furoate/GW642444
Drug: Fluticasone furoate
Drug pages: Fluticasone furoateStudies of Fluticasone furoateFluticasone furoate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VilanterolStudies of VilanterolVilanterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Combination inhaled corticosteroid and long-acting beta2-agonist
Inhaled corticosteroid
Number of Participants With 1 or More Severe Asthma Exacerbations
Asthma is a medical condition that causes narrowing of the small airways in the lungs. A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Only events deemed by the adjudication committee to be severe asthma exacerbations were used in the analysis of severe asthma exacerbations. The time to the first severe asthma exacerbation was analyzed using a Cox proportional hazards regression model, adjusting for Baseline disease severity (Baseline forced expiratory volume in one second \[FEV1, maximum amount of air forcefully exhaled in one second\]), sex, age, and region.
Time frame: Baseline to Follow-up (up to 76 weeks of treatment)
Number of Severe Asthma Exacerbations
A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. A participant may have had one or more exacerbations.
Time frame: Baseline to Follow-up (up to 76 weeks of treatment)
Change From Baseline in Evening Pre-dose Trough FEV1 at Week 36
Evening pre-dose trough (lowest value) forced expiratory volume in one second (FEV1) was measured using spirometry equipment that met or exceeded the minimal performance recommendations of the American Thoracic Society. FEV1 is a measure of the maximum amount of air forcefully exhaled in one second. Change from Baseline in evening pre-dose FEV1 was analyzed using an Analysis of Covariance (ANCOVA) model with effects due to Baseline FEV1, sex, age, region, and treatment. Change from Baseline was calculated as the Week 36 value minus the Baseline value.
Time frame: Baseline and Week 36
| Milestone | FP 250 µg/ICS | FF 100 µg | FF/VI 100/25 µg |
|---|---|---|---|
| Started | 2183 | 0 | 0 |
| Completed | 2020 | 0 | 0 |
| Not completed | 163 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Physician decision | 6 | 0 | 0 |
| Withdrew: Withdrawal by subject | 19 | 0 | 0 |
| Withdrew: Study closed/terminated | 42 | 0 | 0 |
| Withdrew: Continuation criteria not met | 92 | 0 | 0 |
| Withdrew: Randomized in error | 1 | 0 | 0 |
| Milestone | FP 250 µg/ICS | FF 100 µg | FF/VI 100/25 µg |
|---|---|---|---|
| Started | 0 | 1011 | 1009 |
| Completed | 0 | 863 | 885 |
| Not completed | 0 | 148 | 124 |
| Withdrew: Withdrawal by subject | 0 | 53 | 55 |
| Withdrew: Protocol violation | 0 | 26 | 17 |
| Withdrew: Lack of efficacy | 0 | 22 | 13 |
| Withdrew: Adverse event | 0 | 19 | 15 |
| Withdrew: Lost to follow-up | 0 | 11 | 9 |
| Withdrew: Physician decision | 0 | 9 | 6 |
| Withdrew: Study closed/terminated | 0 | 7 | 8 |
| Withdrew: Protocol-defined stopping criteria | 0 | 0 | 1 |
| Withdrew: Received treatment in error | 0 | 1 | 0 |
Asthma is a medical condition that causes narrowing of the small airways in the lungs. A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Only events deemed by the adjudication committee to be severe asthma exacerbations were used in the analysis of severe asthma exacerbations. The time to the first severe asthma exacerbation was analyzed using a Cox proportional hazards regression model, adjusting for Baseline disease severity (Baseline forced expiratory volume in one second \[FEV1, maximum amount of air forcefully exhaled in one second\]), sex, age, and region.
| participants | FF 100 µg | FF/VI 100/25 µg |
|---|---|---|
| Number of Participants With 1 or More Severe Asthma Exacerbations | 186 | 154 |
A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. A participant may have had one or more exacerbations.
| Severe asthma exacerbations | FF 100 µg | FF/VI 100/25 µg |
|---|---|---|
| Number of Severe Asthma Exacerbations | 271 | 200 |
Evening pre-dose trough (lowest value) forced expiratory volume in one second (FEV1) was measured using spirometry equipment that met or exceeded the minimal performance recommendations of the American Thoracic Society. FEV1 is a measure of the maximum amount of air forcefully exhaled in one second. Change from Baseline in evening pre-dose FEV1 was analyzed using an Analysis of Covariance (ANCOVA) model with effects due to Baseline FEV1, sex, age, region, and treatment. Change from Baseline was calculated as the Week 36 value minus the Baseline value.
| Liters | FF 100 µg | FF/VI 100/25 µg |
|---|---|---|
| Change From Baseline in Evening Pre-dose Trough FEV1 at Week 36 | 0.265 ± 0.014 | 0.348 ± 0.014 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FF 100 µg | — | 29/1,010 (2.9%) | 479/1,010 (47.4%) |
| FF/VI 100/25 µg | — | 41/1,009 (4.1%) | 467/1,009 (46.3%) |
| Event | FF 100 µg | FF/VI 100/25 µg |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 9/1010 | 11/1009 |
| PneumoniaInfections and infestations | 4/1010 | 4/1009 |
| Nasal polypsRespiratory, thoracic and mediastinal disorders | 0/1010 | 1/1009 |
| Anal abscessInfections and infestations | 0/1010 | 1/1009 |
| AppendicitisInfections and infestations | 0/1010 | 1/1009 |
| Chronic sinusitisInfections and infestations | 0/1010 | 1/1009 |
| LabyrinthitisInfections and infestations | 0/1010 | 1/1009 |
| Meningitis viralInfections and infestations | 0/1010 | 1/1009 |
| PharyngitisInfections and infestations | 0/1010 | 1/1009 |
| Skin infectionInfections and infestations | 0/1010 | 1/1009 |
| Event | FF 100 µg | FF/VI 100/25 µg |
|---|---|---|
| HeadacheNervous system disorders | 179/1010 | 188/1009 |
| NasopharyngitisInfections and infestations | 131/1010 | 155/1009 |
| Upper respiratory tract infectionInfections and infestations | 93/1010 | 73/1009 |
| BronchitisInfections and infestations | 74/1010 | 59/1009 |
| CoughRespiratory, thoracic and mediastinal disorders | 64/1010 | 55/1009 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 55/1010 | 41/1009 |
| InfluenzaInfections and infestations | 38/1010 | 50/1009 |
| SinusitusInfections and infestations | 38/1010 | 42/1009 |
| Back painMusculoskeletal and connective tissue disorders | 40/1010 | 41/1009 |
| PharyngitisInfections and infestations | 41/1010 | 29/1009 |
| Age, Continuous(Years) | FF 100 µg | FF/VI 100/25 µg | Total |
|---|---|---|---|
| Mean | 42.3 ± 16.82 | 41.1 ± 17.10 | 41.7 ± 16.96 |
| Sex: Female, Male(Participants) | FF 100 µg | FF/VI 100/25 µg | Total |
|---|---|---|---|
| Female | 689 | 661 | 1350 |
| Male | 321 | 348 | 669 |
| Race/Ethnicity, Customized(participants) | FF 100 µg | FF/VI 100/25 µg | Total |
|---|---|---|---|
| African American/African Heritage | 47 | 40 | 87 |
| American Indian or Alaska Native | 4 | 9 | 13 |
| Asian - Central/South Asian Heritage | 0 | 2 | 2 |
| Asian - East Asian Heritage | 1 | 0 | 1 |
| Asian - Japanese Heritage | 30 | 32 | 62 |
| Asian - South East Asian Heritage | 79 | 78 | 157 |
| Native Hawaiian or other Pacific Islander | 2 | 0 | 2 |
| White - Arabic/North African Heritage | 5 | 2 | 7 |
| White - White/Caucasian/European Heritage | 738 | 738 | 1476 |
| Mixed Race | 104 | 108 | 212 |
Showing the first 100 of 183 sites across 11 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Feb 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 2 years after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol